Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
Details : LAVA-1266 is a potent bi-specific, T cell engager that targets CD123+ tumor cells. It is being evaluated for the hematologic cancers including acute myeloid leukemia & myelodysplastic syndrome.
Product Name : LAVA-1266
Product Type : Antibody
Upfront Cash : Inapplicable
January 10, 2025
LAVA Announces Pfizer Milestone for PF-08046052 in Clinical Development
Details : Lava will receive milestone payments for SGN-EGFRd2 (PF-08046052), evaluated for colorectal neoplasms and non-small-cell lung carcinoma treatment.
Product Name : SGN-EGFRd2
Product Type : Other Large Molecule
Upfront Cash : $50.0 million
May 03, 2024
Lead Product(s) : LAVA-1207,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
LAVA Announces Collaboration with Merck To Evaluate LAVA-1207 and KEYTRUDA®
Details : The collaboration evaluates Merck's KEYTRUDA® (pembrolizumab) with LAVA-1207, targeting PSMA to kill PSMA-positive tumor cells in patients with mCRPC.
Product Name : LAVA-1207
Product Type : Antibody
Upfront Cash : Undisclosed
January 25, 2024
Lead Product(s) : LAVA-1207,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : LAVA-1207
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
Details : LAVA-1207 is a Gammabody™ that conditionally activates Vgamma9 Vdelta2 T cells upon crosslinking to PSMA to trigger the potent and preferential killing of PSMA-positive tumor cells, including metastatic castration-resistant prostate cancer.
Product Name : LAVA-1207
Product Type : Antibody
Upfront Cash : Inapplicable
January 23, 2023
Lead Product(s) : LAVA-1207
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : JANSSEN BIOTECH
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Janssen has chosen a lead gamma-delta T-cell engager bispecific antibody candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings for the treatment of cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : JANSSEN BIOTECH
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : LAVA-051
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LAVA-051, is a Gammabody™ that targets CD1d-expressing tumors,uniquely activates both Vγ9Vδ2 T cells as well as invariant natural killer T cells, which represent another conserved immune effector cell population, in a target-dependent manner.
Product Name : LAVA-051
Product Type : Antibody
Upfront Cash : Inapplicable
July 10, 2022
Lead Product(s) : LAVA-051
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LAVA-051
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LAVA-051, a Gammabody designed to activate both Vgamma9 Vdelta2 T cells and type 1 NKT cells to kill CD1d-expressing tumor cells, preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndrome.
Product Name : LAVA-051
Product Type : Antibody
Upfront Cash : Inapplicable
July 03, 2022
Lead Product(s) : LAVA-051
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LAVA-051
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LAVA-051 is a humanized Gammabody™ designed to activate both Vγ9Vδ2 (Vgamma9 Vdelta2) T cells and type 1 NKT cells to kill CD1d-expressing tumor cells.
Product Name : LAVA-051
Product Type : Antibody
Upfront Cash : Inapplicable
June 16, 2022
Lead Product(s) : LAVA-051
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LAVA-051
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LAVA-051, is a Gammabody that targets CD1d-expressing tumors, demonstrated efficacy and safety in a variety of preclinical models,it uniquely activates both Vγ9Vδ2 T cells as well as iNKT cells, which represent another conserved immune effector cell po...
Product Name : LAVA-051
Product Type : Antibody
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : LAVA-051
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LAVA-051
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The dose-escalation data demonstrated a favorable safety profile to date and early encouraging signs of potential anti-tumor activity of LAVA-051, as well as a desirable PK-PD profile, in patients with chronic lymphocytic leukemia and multiple myeloma.
Product Name : LAVA-051
Product Type : Antibody
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : LAVA-051
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable